Mylan Stock Price Target and Analyst Ratings (NASDAQ:MYL)

Analyst Price Target for MYL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$20.33

▲ +28.25% Upside Potential

This price target is based on 7 analysts offering 12 month price targets for Mylan in the last 3 months. The average price target is $20.33, with a high forecast of $27.00 and a low forecast of $16.00. The average price target represents a 28.25% upside from the last price of $15.86.

Hold

The current consensus among 7 investment analysts is to hold stock in Mylan. This rating has held steady since June 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
14 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

8/2/2019

0 strong buy ratings
13 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

10/31/2019

0 strong buy ratings
11 buy ratings
8 hold ratings
0 sell ratings

Ratings as of

1/29/2020

0 strong buy ratings
9 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

4/28/2020

0 strong buy ratings
5 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

7/27/2020

0 strong buy ratings
4 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

10/25/2020

0 strong buy ratings
3 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

12/24/2020

0 strong buy ratings
3 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

1/23/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
10/28/2020	Wells Fargo & Company	Lower Price Target	Equal Weight	$17.00 ➝ $16.00	Medium	i
9/8/2020	Raymond James	Reiterated Rating	Buy		High	i
8/11/2020	UBS Group	Boost Price Target	Neutral	$17.00 ➝ $18.00	Medium	i
5/13/2020	UBS Group	Boost Price Target	Neutral	$16.00 ➝ $17.00	High	i
5/12/2020	Royal Bank of Canada	Reiterated Rating	Buy	$26.00	High	i Rating by Randall Stanicky at Royal Bank of Canada
4/30/2020	Wells Fargo & Company	Lower Price Target	Equal Weight	$23.00 ➝ $18.00	Low	i
4/15/2020	Piper Sandler	Lower Price Target	Neutral	$23.00 ➝ $17.00	Low	i
4/2/2020	Morgan Stanley	Lower Price Target	Equal Weight	$23.00 ➝ $18.00	High	i
3/27/2020	Royal Bank of Canada	Lower Price Target	Outperform	$27.00 ➝ $26.00	Low	i Rating by Randall Stanicky at Royal Bank of Canada
2/5/2020	SunTrust Banks	Reiterated Rating	Buy	$27.00	Medium	i Rating by Gregg Gilbert at SunTrust Banks, Inc.
1/9/2020	Piper Sandler	Initiated Coverage	Neutral	$21.00	Medium	i
1/6/2020	Royal Bank of Canada	Boost Price Target	Outperform	$25.00 ➝ $27.00	High	i
12/16/2019	Evercore ISI	Reiterated Rating	Buy		Medium	i Rating by Umer Raffat at Evercore ISI
11/27/2019	Cfra	Upgrade	Hold		Low	i Rating by Colin Scarola at Cfra
11/7/2019	Morgan Stanley	Downgrade	Overweight ➝ Equal	$25.00 ➝ $18.00	Low	i Rating by David Risinger at Morgan Stanley
11/5/2019	Cfra	Downgrade	Hold ➝ Sell		High	i
9/12/2019	SunTrust Banks	Boost Price Target	Buy	$25.00 ➝ $27.00	Low	i
8/9/2019	Evercore ISI	Reiterated Rating	Buy		N/A	i Rating by Umer Raffat at Evercore ISI
7/31/2019	Citigroup	Set Price Target	Buy	$26.00	Low	i Rating by Liav Abraham at Citigroup Inc.
7/31/2019	Credit Suisse Group	Reiterated Rating	Buy	$34.50	Low	i
7/30/2019	Mizuho	Boost Price Target	Neutral	$25.00 ➝ $27.00	Low	i Rating by Irina Rivkind Koffler at Mizuho
7/30/2019	Morgan Stanley	Reiterated Rating	Overweight	$22.00 ➝ $25.00	Low	i Rating by David Risinger at Morgan Stanley
7/19/2019	Wolfe Research	Initiated Coverage	Outperform ➝ Outperform	$27.00	Low	i
7/15/2019	Morgan Stanley	Set Price Target	Buy	$22.00	Low	i Rating by David Risinger at Morgan Stanley
6/12/2019	Cantor Fitzgerald	Lower Price Target	Neutral	$31.00 ➝ $18.00	Low	i
6/11/2019	Barclays	Initiated Coverage	Overweight ➝ Overweight	$26.00	Medium	i
5/28/2019	UBS Group	Lower Price Target	Neutral	$23.00	Low	i
5/14/2019	Mizuho	Reiterated Rating	Hold		Medium	i Rating by Irina Rivkind Koffler at Mizuho
5/8/2019	Morgan Stanley	Set Price Target	Buy	$32.00	Medium	i Rating by David Risinger at Morgan Stanley
5/8/2019	Raymond James	Set Price Target	Buy	$31.00	Medium	i Rating by Elliot Wilbur at Raymond James
5/8/2019	BMO Capital Markets	Set Price Target	Buy	$36.00	Medium	i Rating by Gary Nachman at BMO Capital Markets
5/8/2019	Royal Bank of Canada	Lower Price Target	Outperform	$26.00	Low	i
5/7/2019	Wells Fargo & Company	Downgrade	Outperform ➝ Market Perform	$33.00 ➝ $22.00	Low	i
4/1/2019	Cantor Fitzgerald	Reiterated Rating	Hold	$41.00	High	i
3/27/2019	Argus	Lower Price Target	Buy	$32.00	Medium	i Rating by Jasper Hellweg at Argus
3/19/2019	SunTrust Banks	Initiated Coverage	Buy ➝ Buy	$35.00	Low	i
3/7/2019	UBS Group	Reiterated Rating	Neutral	$31.00	Low	i
3/6/2019	Credit Suisse Group	Reiterated Rating	Buy	$37.00	Low	i
3/6/2019	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$35.00	Medium	i Rating by David Risinger at Morgan Stanley
2/27/2019	Wells Fargo & Company	Lower Price Target	Outperform	$40.00 ➝ $33.00	High	i Rating by David Maris at Wells Fargo & Company
2/27/2019	BTIG Research	Lower Price Target	Buy	$35.00	High	i
2/27/2019	BMO Capital Markets	Boost Price Target	Outperform	$40.00	High	i
2/27/2019	Sanford C. Bernstein	Downgrade	Outperform ➝ Market Perform	$33.00	High	i
1/31/2019	Mizuho	Reiterated Rating	Neutral		High	i Rating by I. Koffler at Mizuho
1/23/2019	UBS Group	Downgrade	Buy ➝ Neutral	$54.00 ➝ $32.00	Medium	i
11/20/2018	Cantor Fitzgerald	Reiterated Rating	Hold	$41.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
11/15/2018	Argus	Upgrade	Hold ➝ Buy	$42.00	Medium	i
11/6/2018	JPMorgan Chase & Co.	Set Price Target	Buy	$45.00	Low	i Rating by Chris Schott at JPMorgan Chase & Co.
11/6/2018	Wells Fargo & Company	Upgrade	Market Perform ➝ Buy	$40.00	High	i Rating by David Maris at Wells Fargo & Company
11/6/2018	Royal Bank of Canada	Lower Price Target	Outperform ➝ Buy	$51.00 ➝ $50.00	High	i Rating by Randall Stanicky at Royal Bank of Canada
11/6/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Hold	$36.00 ➝ $39.00	High	i Rating by David Risinger at Morgan Stanley
11/6/2018	Citigroup	Lower Price Target	Buy ➝ Buy	$48.00 ➝ $44.00	High	i
11/6/2018	Cowen	Set Price Target	Hold	$31.00	High	i Rating by Ken Cacciatore at Cowen Inc
11/6/2018	Bank of America	Upgrade	Neutral ➝ Buy	$44.00 ➝ $42.00	High	i
11/5/2018	Cantor Fitzgerald	Reiterated Rating	Hold	$41.00	High	i Rating by Louise Chen at Cantor Fitzgerald
10/9/2018	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$46.00 ➝ $36.00	Low	i
10/5/2018	Mizuho	Downgrade	Buy ➝ Neutral		Low	i Rating by I. Koffler at Mizuho
8/24/2018	Evercore ISI	Upgrade	In-Line ➝ Outperform		Low	i
8/15/2018	Wells Fargo & Company	Reiterated Rating	Hold		Low	i Rating by David Maris at Wells Fargo & Company
8/13/2018	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$53.00	Low	i Rating by Randall Stanicky at Royal Bank of Canada
8/9/2018	Citigroup	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $48.00	High	i
8/9/2018	SVB Leerink	Lower Price Target	Outperform	$53.00 ➝ $47.00	High	i Rating by A. Fadia at SVB Leerink LLC
8/9/2018	Raymond James	Downgrade	Strong-Buy ➝ Outperform		High	i
8/9/2018	Cowen	Reiterated Rating	Hold	$31.00	High	i
8/8/2018	Cantor Fitzgerald	Reiterated Rating	Hold	$41.00	High	i Rating by Louise Chen at Cantor Fitzgerald
8/8/2018	Wells Fargo & Company	Set Price Target	Hold	$41.00	High	i Rating by David Maris at Wells Fargo & Company
8/8/2018	Mizuho	Reiterated Rating	Buy	$54.00	High	i
8/2/2018	Wells Fargo & Company	Reiterated Rating	Hold		Low	i Rating by David Maris at Wells Fargo & Company
7/25/2018	Wells Fargo & Company	Reiterated Rating	Hold		Medium	i Rating by David Maris at Wells Fargo & Company
6/29/2018	Cantor Fitzgerald	Set Price Target	Hold	$41.00	Medium	i Rating by Louise Chen at Cantor Fitzgerald
6/14/2018	Guggenheim	Reiterated Rating	Buy	$59.00	Medium	i
6/6/2018	Guggenheim	Reiterated Rating	Buy	$59.00	Medium	i
5/31/2018	Wells Fargo & Company	Set Price Target	Market Perform ➝ Hold	$43.00 ➝ $41.00	High	i Rating by David Maris at Wells Fargo & Company
5/29/2018	Bank of America	Lower Price Target	Neutral ➝ Neutral	$43.00 ➝ $42.00	Medium	i
5/23/2018	JPMorgan Chase & Co.	Set Price Target	Buy	$53.00	Low	i Rating by Chris Schott at JPMorgan Chase & Co.
5/9/2018	Cantor Fitzgerald	Set Price Target	Hold	$41.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
4/23/2018	Wells Fargo & Company	Reiterated Rating	Hold		Low	i Rating by David Maris at Wells Fargo & Company
4/12/2018	JPMorgan Chase & Co.	Set Price Target	Buy	$53.00	Low	i Rating by Chris Schott at JPMorgan Chase & Co.
4/12/2018	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$44.00	Low	i Rating by A. Fadia at SVB Leerink LLC
4/11/2018	Cantor Fitzgerald	Set Price Target	Hold	$41.00	Medium	i Rating by Louise Chen at Cantor Fitzgerald
4/9/2018	Morgan Stanley	Set Price Target	Buy	$50.00	High	i Rating by David Risinger at Morgan Stanley
4/3/2018	Royal Bank of Canada	Set Price Target	Hold	$45.00	Low	i Rating by Randall Stanicky at Royal Bank of Canada
3/15/2018	Mizuho	Boost Price Target	Buy	$45.00 ➝ $51.00	Low	i
3/6/2018	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$39.00 ➝ $50.00	Medium	i
3/1/2018	UBS Group	Set Price Target	Buy	$54.00	High	i Rating by Marc Goodman at UBS Group AG
3/1/2018	Cantor Fitzgerald	Set Price Target	Hold	$41.00	Medium	i Rating by Louise Chen at Cantor Fitzgerald
2/16/2018	JPMorgan Chase & Co.	Set Price Target	Buy	$53.00	Low	i Rating by Chris Schott at JPMorgan Chase & Co.
1/25/2018	140166	Reiterated Rating	Positive ➝ Positive	$47.00 ➝ $55.00	Low	i
1/24/2018	Deutsche Bank Aktiengesellschaft	Set Price Target	Buy	$50.00	Low	i Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
1/18/2018	Wells Fargo & Company	Set Price Target	Hold	$33.00 ➝ $43.00	Low	i
1/11/2018	The Goldman Sachs Group	Boost Price Target	Buy	$46.00 ➝ $52.00	High	i
1/4/2018	Citigroup	Reiterated Rating	Buy ➝ Buy	$48.00 ➝ $58.00	High	i
1/2/2018	SVB Leerink	Initiated Coverage	Mkt Perform ➝ Market Perform	$44.00	Low	i Rating by A. Fadia at SVB Leerink LLC
12/26/2017	Cantor Fitzgerald	Set Price Target	Hold	$41.00	Low	i Rating by Louise Chen at Cantor Fitzgerald
12/12/2017	Guggenheim	Initiated Coverage	Buy ➝ Buy	$59.00	Low	i
12/4/2017	UBS Group	Set Price Target	Buy	$46.00	Low	i Rating by Marc Goodman at UBS Group AG
11/30/2017	Cantor Fitzgerald	Set Price Target	Hold	$34.00	Medium	i Rating by Louise Chen at Cantor Fitzgerald
11/7/2017	Royal Bank of Canada	Boost Price Target	Sector Perform ➝ Sector Perform	$32.00 ➝ $37.00	N/A	i
10/31/2017	Cantor Fitzgerald	Set Price Target	Hold	$34.00	N/A	i
10/24/2017	Mizuho	Reiterated Rating	Buy	$37.00	N/A	i
10/20/2017	Royal Bank of Canada	Set Price Target	Hold	$32.00	N/A	i
10/6/2017	JPMorgan Chase & Co.	Reiterated Rating	Overweight	$44.00 ➝ $48.00	N/A	i
10/6/2017	Morgan Stanley	Boost Price Target	Equal Weight	$36.00 ➝ $39.00	N/A	i
10/5/2017	UBS Group	Reiterated Rating	Buy	$46.00	N/A	i
10/5/2017	Nomura Instinet	Reiterated Rating	Buy	$37.00	N/A	i
10/5/2017	Cowen	Reiterated Rating	Market Perform	$30.00 ➝ $36.00	N/A	i
10/4/2017	Citigroup	Set Price Target	Buy	$42.00	N/A	i
10/4/2017	Mizuho	Reiterated Rating	Buy	$37.00	N/A	i
10/4/2017	Wells Fargo & Company	Set Price Target	Hold	$30.00 ➝ $32.00	N/A	i
10/4/2017	Cantor Fitzgerald	Reiterated Rating	Hold	$34.00	High	i
10/4/2017	BTIG Research	Boost Price Target	Buy ➝ Buy	$42.00 ➝ $45.00	High	i
9/29/2017	BMO Capital Markets	Reiterated Rating	Buy	$45.00	Low	i
9/8/2017	Cantor Fitzgerald	Reiterated Rating	Hold	$34.00	Low	i
8/22/2017	Argus	Downgrade	Buy ➝ Hold	$47.59 ➝ $29.39	Low	i
8/20/2017	Mizuho	Reiterated Rating	Buy	$53.00 ➝ $37.00	Low	i
8/16/2017	Citigroup	Upgrade	Neutral ➝ Buy	$36.00 ➝ $42.00	Medium	i
8/10/2017	UBS Group	Reiterated Rating	Buy	$50.00 ➝ $46.00	High	i
8/10/2017	BMO Capital Markets	Reiterated Rating	Outperform	$50.00 ➝ $45.00	High	i
8/10/2017	Royal Bank of Canada	Reiterated Rating	Sector Perform	$33.00 ➝ $32.00	Low	i
8/9/2017	Cowen	Reiterated Rating	Hold	$43.00 ➝ $30.00	Medium	i
8/9/2017	Cantor Fitzgerald	Set Price Target	Hold	$34.00	Medium	i
8/9/2017	Wells Fargo & Company	Set Price Target	Hold	$34.50 ➝ $30.00	Medium	i
8/7/2017	Morgan Stanley	Lower Price Target	Equal ➝ Equal Weight	$52.00 ➝ $36.00	Medium	i
8/4/2017	Royal Bank of Canada	Reiterated Rating	Hold	$41.00 ➝ $33.00	High	i
8/3/2017	Cowen	Reiterated Rating	Hold	$43.00	High	i
7/16/2017	Royal Bank of Canada	Set Price Target	Hold	$41.00	Medium	i
6/16/2017	Cantor Fitzgerald	Initiated Coverage	Neutral ➝ Neutral	$41.00	Low	i
6/13/2017	Royal Bank of Canada	Reiterated Rating	Hold	$41.00	High	i
5/31/2017	Wells Fargo & Company	Reiterated Rating	Market Perform	$40.00	Medium	i
5/22/2017	Barclays	Upgrade	Equal Weight ➝ Overweight	$47.00 ➝ $50.00	Low	i
5/21/2017	Cowen	Reiterated Rating	Market Perform	$55.00 ➝ $43.00	Medium	i
5/13/2017	Royal Bank of Canada	Set Price Target	Hold	$41.00	Low	i
5/11/2017	Royal Bank of Canada	Lower Price Target	Sector Perform	$39.00 ➝ $36.00	Low	i
5/1/2017	BMO Capital Markets	Initiated Coverage	Outperform	$50.00	Low	i
4/18/2017	Deutsche Bank Aktiengesellschaft	Lower Price Target	Buy	$52.00 ➝ $51.00	Low	i
4/17/2017	Royal Bank of Canada	Reiterated Rating	Sector Perform ➝ Sector Perform	$48.00 ➝ $46.00	Low	i
4/14/2017	Wells Fargo & Company	Reiterated Rating	Market Perform	$40.00	N/A	i
3/30/2017	SVB Leerink	Reiterated Rating	Outperform	$52.00	Low	i
3/30/2017	Mizuho	Reiterated Rating	Buy	$53.00	Low	i
3/30/2017	Royal Bank of Canada	Reiterated Rating	Sector Perform	$48.00	Low	i
3/20/2017	SVB Leerink	Reiterated Rating	Outperform		Low	i
3/13/2017	Mizuho	Boost Price Target	Buy ➝ Buy	$47.00 ➝ $53.00	Low	i
3/11/2017	Barclays	Reiterated Rating	Equal Weight	$44.00 ➝ $47.00	N/A	i
3/6/2017	SVB Leerink	Reiterated Rating	Outperform	$52.00	N/A	i
3/3/2017	Guggenheim	Reiterated Rating	Neutral		N/A	i
3/2/2017	Royal Bank of Canada	Set Price Target	Hold	$44.00 ➝ $48.00	N/A	i
2/28/2017	Mizuho	Reiterated Rating	Buy	$47.00	N/A	i
1/5/2017	Guggenheim	Reiterated Rating	Neutral		N/A	i
1/5/2017	Citigroup	Downgrade	Buy ➝ Neutral	$59.00 ➝ $44.00	N/A	i
1/3/2017	BTIG Research	Reiterated Rating	Buy	$55.00	N/A	i
12/30/2016	Stifel Nicolaus	Reiterated Rating	Positive		N/A	i
12/7/2016	Mizuho	Reiterated Rating	Buy	$49.00 ➝ $47.00	N/A	i
11/29/2016	BTIG Research	Reiterated Rating	Buy	$55.00	N/A	i
11/18/2016	Mizuho	Lower Price Target	Buy	$49.00 ➝ $47.00	N/A	i
11/10/2016	Royal Bank of Canada	Reiterated Rating	Sector Perform	$48.00 ➝ $44.00	N/A	i
11/10/2016	Barclays	Reiterated Rating	Hold	$44.00	N/A	i
10/26/2016	Mizuho	Initiated Coverage	Buy	$49.00	N/A	i
10/10/2016	JPMorgan Chase & Co.	Set Price Target	Buy	$52.00	N/A	i
10/10/2016	BTIG Research	Reiterated Rating	Buy	$55.00	N/A	i
10/10/2016	Royal Bank of Canada	Reiterated Rating	Sector Perform	$48.00	N/A	i
10/10/2016	UBS Group	Reiterated Rating	Buy	$66.00 ➝ $60.00	N/A	i
10/10/2016	Raymond James	Upgrade	Market Perform ➝ Strong-Buy	$57.00	N/A	i
10/10/2016	UBS Group	Upgrade	Market Perform ➝ Strong-Buy		N/A	i
10/4/2016	JPMorgan Chase & Co.	Set Price Target	Buy	$52.00	N/A	i
10/1/2016	SVB Leerink	Set Price Target	Buy	$55.00 ➝ $45.00	N/A	i
10/1/2016	Wells Fargo & Company	Set Price Target	Hold	$44.00	N/A	i
9/23/2016	Sanford C. Bernstein	Set Price Target	Buy	$60.00	N/A	i
9/23/2016	Deutsche Bank Aktiengesellschaft	Set Price Target	Buy	$60.00 ➝ $58.00	N/A	i
9/22/2016	SVB Leerink	Reiterated Rating	Buy		N/A	i
9/22/2016	Argus	Set Price Target	Buy	$55.00	N/A	i
9/6/2016	Royal Bank of Canada	Lower Price Target	Sector Perform	$52.00 ➝ $48.00	N/A	i
9/4/2016	Wells Fargo & Company	Set Price Target	Hold	$44.00	N/A	i
8/30/2016	BTIG Research	Reiterated Rating	Buy	$60.00	N/A	i
8/30/2016	SVB Leerink	Reiterated Rating	Outperform	$55.00	N/A	i
8/26/2016	Evercore ISI	Reiterated Rating	Hold	$49.00	N/A	i
8/25/2016	The Goldman Sachs Group	Reiterated Rating	Conviction-Buy	$60.00	N/A	i
8/25/2016	Wells Fargo & Company	Reiterated Rating	Market Perform	$44.00	N/A	i
8/24/2016	Bank of America	Reiterated Rating	Buy	$70.00	N/A	i
8/15/2016	SVB Leerink	Boost Price Target	Outperform	$51.00 ➝ $55.00	N/A	i
7/12/2016	Morgan Stanley	Reiterated Rating	Hold		N/A	i
6/25/2016	JPMorgan Chase & Co.	Reiterated Rating	Overweight		N/A	i
5/17/2016	UBS Group	Reiterated Rating	Buy	$66.00	N/A	i
5/13/2016	The Goldman Sachs Group	Downgrade	Conviction-Buy ➝ Buy	$60.00	N/A	i
5/4/2016	SVB Leerink	Lower Price Target	Outperform	$53.00 ➝ $51.00	N/A	i
4/26/2016	The Goldman Sachs Group	Reiterated Rating	Buy		N/A	i
3/21/2016	Wells Fargo & Company	Reiterated Rating	Market Perform		N/A	i
3/8/2016	BTIG Research	Reiterated Rating	Buy	$60.00	N/A	i
2/19/2016	Argus	Lower Price Target	Buy	$65.00 ➝ $55.00	N/A	i
2/19/2016	Wells Fargo & Company	Initiated Coverage	Market Perform		N/A	i
2/16/2016	SVB Leerink	Lower Price Target	Outperform	$53.00 ➝ $50.00	N/A	i
2/11/2016	Citigroup	Reiterated Rating	Buy		N/A	i
2/11/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A	i
2/11/2016	Guggenheim	Reiterated Rating	Neutral		N/A	i
2/11/2016	Royal Bank of Canada	Reiterated Rating	Hold	$60.00 ➝ $58.00	N/A	i
2/11/2016	Cowen	Lower Price Target	Market Perform	$65.00 ➝ $55.00	N/A	i

(Data available from 1/24/2016 forward)

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.

Today's Range

Now: $15.86

$15.34

$16.15

50 Day Range

MA: $15.57

$14.37

$15.86

52 Week Range

Now: $15.86

$12.75

$23.11

Volume

14,100,488 shs

Average Volume

6,488,034 shs

Market Capitalization

$8.59 billion

P/E Ratio

29.92

Dividend Yield

N/A

Beta

1.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Mylan?

The following Wall Street research analysts have issued stock ratings on Mylan in the last year: Morgan Stanley, Piper Sandler, Raymond James, Royal Bank of Canada, SunTrust Banks, Inc., TheStreet, UBS Group AG, and Wells Fargo & Company.

What is the current price target for Mylan?

6 Wall Street analysts have set twelve-month price targets for Mylan in the last year. Their average twelve-month price target is $20.33, suggesting a possible upside of 28.2%. SunTrust Banks, Inc. has the highest price target set, predicting MYL will reach $27.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $16.00 for Mylan in the next year.

What is the current consensus analyst rating for Mylan?

Mylan currently has 4 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MYL, but not buy more shares or sell existing shares.

What other companies compete with Mylan?

Other companies that are similar to Mylan include Johnson & Johnson, Merck & Co., Inc., Pfizer, Eli Lilly and, AbbVie, Bristol-Myers Squibb, Zoetis, Royalty Pharma, Horizon Therapeutics Public, Jazz Pharmaceuticals, Perrigo, Corcept Therapeutics, Nektar Therapeutics, Pacira BioSciences and Endo International.

How do I contact Mylan's investor relations team?

Mylan's physical mailing address is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. The company's listed phone number is 724-514-1800 and its investor relations email address is [email protected] The official website for Mylan is www.mylan.com.

NASDAQ:MYL - Mylan Stock Price Target and Predictions

Analyst Price Target for MYL

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Mylan?

What is the current price target for Mylan?

What is the current consensus analyst rating for Mylan?

What other companies compete with Mylan?

How do I contact Mylan's investor relations team?